Novo Nordisk

Maziar Mike Doustdar promised −5 to −13%. Now it is 0 to −6% (raised).

🇩🇰 Denmark · Medicines

Novo Nordisk0.0Integrity Maziar Mike Doustdar

Maziar Mike DoustdarPresident & CEO, 2025–, Novo NordiskPromisedsales in 2026−5 to −13%3 February 2026

🇩🇰 Denmark · Medicines

Novo Nordisk0.0Integrity Maziar Mike Doustdar

Maziar Mike DoustdarPresident & CEO, 2025–, Novo Nordisk

Will Novo Nordisk's sales drop less than 3% in 2026?

The new promiseSales in 2026 drop less than 3%, or grow.

Max Noble Odds: 55% chance he keeps it. They move with every call. Against the odds you win more, and lose more.

He promised

Sales would drop 5 to 13% in 2026, leaving out a one-off refund.

Maziar Mike Doustdar, President & CEO, 2025–, on 3 February 2026.

He got

Raised twice: now a drop of 0 to 6%. Sales grew 2% in the first half.

Stamp: On track.

Why, says the company

It now expects to sell more of its diabetes and weight-loss medicines, in the US and abroad.

How bad

Nothing yet: the promise was raised. The 2026 annual report settles it. Score 0.0 → 0.0.

In the company’s own words

The company raised its outlook mainly on higher expectations for sales of its GLP-1 medicines (for diabetes and weight loss), with growth and new launches outside the US.

The sources

Will Novo Nordisk's sales drop less than 3% in 2026? Make your call in the CEO Game →